Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome
Shots:
- Health Canada accepted New Drug Submission (NDS) for Acadia’s Trofinetide to treat Rett Syndrome; also granted priority review
- P-III LAVENDER study (n=187) evaluated safety and efficacy of Trofinetide in Rett Syndrome girls & young women; At wk12, co-1EP’s RSBQ score, and CGI-I score, were statistically significant; 2EP: statistically significant measuring improvements in communication
- Trofinetide is currently not permitted for sale in Canada, but has been approved in US for adults and pediatric patients aged >2yrs
Ref: Health Canada | Image: Health Canada
Related News:- Innodem Neuroscience’s ETNA-MS Receives Health Canada’s Approval for the Treatment of Multiple Sclerosis (MS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
